title: Ipilimumab-related hypophysitis may precede severe CNS immune attack.
authors.affiliation: Center of Oncology thibaud.kossler@hcuge.ch.
authors.forename: T
authors.initials: T
authors.lastname: Köessler
authors.affiliation: Center of Oncology.
authors.forename: T
authors.initials: T
authors.lastname: Olivier
authors.affiliation: Center of Oncology.
authors.forename: S
authors.initials: S
authors.lastname: Fertani
authors.affiliation: Center of Oncology Laboratory of Tumor Immunology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: Marinari
authors.affiliation: Center of Oncology Laboratory of Tumor Immunology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
authors.forename: V
authors.initials: V
authors.lastname: Dutoit
authors.affiliation: Center of Oncology Laboratory of Tumor Immunology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
authors.forename: P-Y
authors.initials: PY
authors.lastname: Dietrich
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000072659:Hypophysitis / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology*; D000074324:Ipilimumab / Q000009:adverse effects*; D008875:Middle Aged; D012720:Severity of Illness Index
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab